Interestingly the GLP-1 receptor (GLP1R) agonists liraglutide and semaglutide as well as the orlistat have shown beneficial effects on the two hits typical of NAFLD, the hepatic steatosis and the inflammatory process (for review see (Polyzos et al., 2022)). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.